Needham & Company raised its price target on CONMED (NASDAQ: CNMD) to $71.00 (from $58.00) while maintaining a Buy rating.Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

CONMED (CNMD) PT Raised to $54 at Piper JaffrayFebruary 1, 2018 6:41 AM CONMED (CNMD) PT Raised to $64 at Deutsche Bank, 'Turnaround Continues'February 1, 2018 5:06 AM Conmed (CNMD) Tops Q4 EPS by 4c, Beats on Revenues; Offers FY18 EPS Outlook Above ConsensusJanuary 31, 2018 4:07 PM CONMED Corporation Announces Fourth Quarter and Fiscal Year 2017 Financial ResultsJanuary 31, 2018 4:01 PM